Autolus Therapeutics Q3 2026 net loss narrows 30% year over year to $55.09 million
AUTL•Autolus Therapeutics’ third-quarter net loss narrowed 30% year over year to $55.1 million, while AUCATZYL revenue rose 95% to $41.2 million; the company expects full-year revenue to reach or exceed its prior $150 million upper guidance level.
1. Quarterly results and outlook
Autolus Therapeutics reported a third-quarter 2026 net loss of $55.1 million, down 30% year over year. AUCATZYL net product revenue increased 95% to $41.2 million, driven primarily by increasing demand, and gross margin rose to 57% from 55% in the second quarter, supported by manufacturing efficiencies. The company expects full-year 2026 AUCATZYL revenue to reach or exceed the prior guidance’s $150 million upper end. Initial progressive multiple sclerosis trial data have been postponed to October 2027 to allow longer follow-up.
